Read by QxMD icon Read

Remission depression

Duan Zeng, Shen He, Shunying Yu, Guanjun Li, Changlin Ma, Yi Wen, Yifeng Shen, Yimin Yu, Huafang Li
Background: Increasing evidence has indicated that dysfunction of miR-124 and target gene regulator of G protein signaling 4 ( RGS4 ) may be involved in the etiology and treatment of major depressive disorder (MDD). However, the molecular mechanisms are not fully understood. This study aimed to investigate whether common genetic variations in these two genes are associated with MDD and therapeutic response to antidepressants in the Chinese population. Methods: Three polymorphisms including rs531564 (a functional single-nucleotide polymorphism [SNP] in MIR124-1 ), rs10759 (a microRNA-binding site SNP in RGS4 ), and rs951436 (a promoter SNP in RGS4 ) were genotyped in 225 Chinese MDD patients and 436 controls...
2018: Neuropsychiatric Disease and Treatment
V E Medvedev, A Yu Ter-Israelyan, V I Frolova, E A Korovyakova, E V Gushanskaya
AIM: To investigate the efficacy and tolerability of monotherapy with agomelatine (valdoxan) in depressive patients with marked cognitive impairment. MATERIAL AND METHODS: Thirty-five patients (women 77.1%) were recruited to participate in the study. Mean age of patients was 48.9±3.5 years. The following scales and cognitive tests were used: HAM-21, CGI, HADS, MMSE, the Stroop task, the Rey test, RAVLT. Effective therapeutic doses of valdoxan were 25mg per day in 77...
2018: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
Azmeraw T Amare, Klaus Oliver Schubert, Fasil Tekola-Ayele, Yi-Hsiang Hsu, Katrin Sangkuhl, Gregory Jenkins, Ryan M Whaley, Poulami Barman, Anthony Batzler, Russ B Altman, Volker Arolt, Jürgen Brockmöller, Chia-Hui Chen, Katharina Domschke, Daniel K Hall-Flavin, Chen-Jee Hong, Ari Illi, Yuan Ji, Olli Kampman, Toshihiko Kinoshita, Esa Leinonen, Ying-Jay Liou, Taisei Mushiroda, Shinpei Nonen, Michelle K Skime, Liewei Wang, Masaki Kato, Yu-Li Liu, Verayuth Praphanphoj, Julia C Stingl, William V Bobo, Shih-Jen Tsai, Michiaki Kubo, Teri E Klein, Richard M Weinshilboum, Joanna M Biernacka, Bernhard T Baune
Studies reported a strong genetic correlation between the Big Five personality traits and major depressive disorder (MDD). Moreover, personality traits are thought to be associated with response to antidepressants treatment that might partly be mediated by genetic factors. In this study, we examined whether polygenic scores (PGSs) derived from the Big Five personality traits predict treatment response and remission in patients with MDD who were prescribed selective serotonin reuptake inhibitors (SSRIs). In addition, we performed meta-analyses of genome-wide association studies (GWASs) on these traits to identify genetic variants underpinning the cross-trait polygenic association...
2018: Frontiers in Psychiatry
Joanne Gourgouvelis, Paul Yielder, Sandra T Clarke, Hushyar Behbahani, Bernadette Ann Murphy
Objective: The aim of this study is to investigate the effects of exercise as an add-on therapy with antidepressant medication and cognitive behavioral group therapy (CBGT) on treatment outcomes in low-active major depressive disorder (MDD) patients. We also explored whether exercise reduces the residual symptoms of depression, notably cognitive impairment and poor sleep quality, and aimed to identify putative biochemical markers related to treatment response. Methods: Sixteen low-active MDD patients were recruited from a mental health day treatment program at a local hospital...
2018: Frontiers in Psychiatry
Xinyuan Li, Lijun Zhu, Chunkui Zhou, Jing Liu, Heqian Du, Chenglin Wang, Shaokuan Fang
OBJECTIVE: To investigate the efficacy and tolerability of duloxetine during short-term treatment in adults with generalized anxiety disorder (GAD). METHODS: We conducted a comprehensive literature review of the PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, and ClinicalTrials databases for randomized controlled trials(RCTs) comparing duloxetine or duloxetine plus other antipsychotics with placebo for the treatment of GAD in adults...
2018: PloS One
Ranganathan Vatsala, Panneerselvam Elavenil, Chellappazham Saravanan, Balasubramaniam Sasikala, Raja V B Krishnakumar
PURPOSE: Maxillofacial injuries can result in psychological derangement, leading to post-traumatic stress disorder (PTSD), which is characterized by continual re-experiencing of any traumatic event in addition to numerous systemic complications. The objective of this study was to assess the incidence and severity of "PTSD-related depression" in patients with maxillofacial injuries and to identify the risk factors involved. MATERIALS AND METHODS: This prospective study involved 88 patients with maxillofacial trauma who had only cosmetic deficits (group A), only functional deficits (group B), or cosmetic and functional deficits (group C)...
February 21, 2018: Journal of Oral and Maxillofacial Surgery
David D Ebert, Claudia Buntrock, Jo Annika Reins, Johannes Zimmermann, Pim Cuijpers
INTRODUCTION: The long-term effectiveness of psychological interventions for the treatment of subthreshold depression and the prevention of depression is unclear and effects vary among subgroups of patients, indicating that not all patients profit from such interventions. Randomised clinical trials are mostly underpowered to examine adequately subgroups and moderator effects. The aim of the present study is, therefore, to examine the short-term and long-term as well as moderator effects of psychological interventions compared with control groups in adults with subthreshold depression on depressive symptom severity, treatment response, remission, symptom deterioration, quality of life, anxiety and the prevention of major depressive disorder (MDD) onsets on individual patient level and study level using an individual patient data meta-analysis approach...
March 16, 2018: BMJ Open
Yasodha Maheshi Rohanachandra, Shamini Prathapan, Gampolage Swarna Wijetunge
INTRODUCTION: Maternal depression has been shown to be associated with neurodevelopmental, emotional and behavioural disorders in offspring. We aimed to describe the proportion of psychological problems among children of mothers with depression in Sri Lanka and to describe the association with the characteristics of the mothers' illness. METHODS: A cross-sectional descriptive study was conducted on 100 children and adolescents between 4-16 years whose mother has a diagnosis of depression and currently in remission...
March 3, 2018: Asian Journal of Psychiatry
Igor Filipčić, Ivona Šimunović Filipčić, Tomislav Gajšak, Željko Milovac, Strahimir Sučić, Ena Ivezić, Sandra Zečević Penić, Ivana Orgulan, Damir Šebo, Vjekoslav Jeleč, Žarko Bajić
Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive technique with few side effects that has been reported to be effective in the treatment of major depressive disorder (MDD). At present, no randomized controlled trials (RCT) have compared the efficacy and safety of rTMS delivered by the figure-8-coil and the H1-coil. We describe an industry-independent, randomized, controlled, single-blinded, single-center study protocol assessing the differences in efficacy and safety of rTMS for patients diagnosed with MDD with the H1-coil and figure-8-coil as an add-on to stable pharmacotherapy or pharmacotherapy alone...
March 2018: Psychiatria Danubina
Hannah Maier, Saskia Helm, Sermin Toto, Nicole Moschny, Wolfgang Sperling, Thomas Hillemacher, Kai G Kahl, Ewgeni Jakubovski, Stefan Bleich, Helge Frieling, Alexandra Neyazi
Background: Electroconvulsive therapy (ECT) is one of the most effective treatment options for refractory depressed patients. To date, there are only a few predictors of response. Aim: The aim was to identify predictive biomarkers of remission to ECT on a molecular level. Methods: 11 patients suffering from a major depressive episode-according to the Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)-underwent 10 ECT sessions...
2018: Disease Markers
Bruno Romeo, Lisa Blecha, Katia Locatelli, Amine Benyamina, Catherine Martelli
The objective of this meta-analysis is to assess the efficacy and safety of partial and complete dopamine agonists in the treatment of acute mood disorder episodes. Randomized, double-blind and placebo-controlled trials of dopamine agonists in the treatment of acute mood disorder episodes were identified in the MEDLINE and PsycINFO databases and included in the meta-analysis. In monotherapy of mania, improved remission rates were found for cariprazine (odds ratio (OR): 2.08, P < 0.01) and for high-dose aripiprazole (OR: 3...
March 1, 2018: Journal of Psychopharmacology
Gin S Malhi, Tim Outhred, Grace Morris, Philip M Boyce, Richard Bryant, Paul B Fitzgerald, Malcolm J Hopwood, Bill Lyndon, Roger Mulder, Greg Murray, Richard J Porter, Ajeet B Singh, Kristina Fritz
In December 2015, the Royal Australian and New Zealand College of Psychiatrists published a comprehensive set of mood disorder clinical practice guidelines for psychiatrists, psychologists and mental health professionals. This guideline summary, directed broadly at primary care physicians, is an abridged version that focuses on bipolar disorder. It is intended as an aid to the management of this complex disorder for primary care physicians working in collaboration with psychiatrists to implement successful long term management...
March 19, 2018: Medical Journal of Australia
Fereshte Ashtari, Nafiseh Esmaeil, Marjan Mansourian, Parinaz Poursafa, Omid Mirmosayyeb, Mahdi Barzegar, Hajar Pourgheisari
The evidence for an impact of ambient air pollution on the incidence and severity of multiple sclerosis (MS) is still limited. In the present study, we assessed the association between daily air pollution levels and MS prevalence and severity in Isfahan city, Iran. Data related to MS patients has been collected from 2008 to 2016 in a referral university clinic. The air quality index (AQI) data, were collected from 6 monitoring stations of Isfahan department of environment. The distribution map presenting the sites of air pollution monitoring stations as well as the residential address of MS patients was plotted on geographical information system (GIS)...
March 2, 2018: Journal of Neuroimmunology
Manish K Jha, Shereen Wakhlu, Neha Dronamraju, Abu Minhajuddin, Tracy L Greer, Madhukar H Trivedi
BACKGROUND: Currently, there are no valid clinical or biological markers to personalize the treatment of depression. Recent evidence suggests that body mass index (BMI) may guide the selection of antidepressant medications with different mechanisms of action. METHODS: Combining Medications to Enhance Depression Outcomes (CO-MED) trial participants with BMI measurement (n = 662) were categorized as normal- or underweight (<25), overweight (25-<30), obese I (30-<35), and obese II+ (≥35)...
February 27, 2018: Journal of Affective Disorders
Di Ye, Li Zhang, Weidong Fan, Xianquan Zhang, Erbo Dong
Synthetic antidepressants in current use for the complex etiopathogeneses of depression have slow response and remission as well as various unpleasant side effects. As a result, it is imperative to develop new antidepressants with more effectiveness and less severe side effects. Recent studies demonstrated that genipin, the aglycon of geniposide, extracted from Gardenia jasminoides Ellis has antidepressive effects. However, knowledge regarding the molecular mechanisms of its antidepressant effects remains limited...
March 9, 2018: Epigenetics: Official Journal of the DNA Methylation Society
Robert M Carney, Kenneth E Freedland, Brian C Steinmeyer, Eugene H Rubin, Michael W Rich
OBJECTIVE: Depression is associated with an increased risk of mortality in patients with coronary heart disease (CHD). The risk may be reduced in patients who remit with adequate treatment, but few patients achieve complete remission. The purpose of this study was to identify the symptoms that persist despite aggressive treatment for depression in patients with CHD. METHODS: One hundred twenty-five patients with stable CHD who met the DSM-IV criteria for a moderate-to-severe major depressive episode completed treatment with cognitive behavior therapy (CBT), either alone or combined with an antidepressant, for up to 16 weeks...
March 8, 2018: Psychosomatic Medicine
Marcela Valdés-Tovar, Rosa Estrada-Reyes, Héctor Solís-Chagoyán, Jesús Argueta, Ana María Dorantes-Barrón, Daniel Quero-Chávez, Ricardo Cruz-Garduño, Montserrat G Cercós, Citlali Trueta, Julián Oikawa-Sala, Margarita L Dubocovich, Gloria Benítez-King
Mood disorders are a spectrum of neuropsychiatric disorders characterized by changes in the emotional state. In particular, major depressive disorder is expected to have a worldwide prevalence of 20% in 2020, representing a huge socioeconomic burden. Currently used antidepressant drugs have poor efficacy with only 30% of the patients getting in remission after the first-line of treatment. Importantly, mood disorder patients present uncoupling of circadian rhythms. In this regard, melatonin (5-methoxy-N-acetyltryptamine) an indolamine synthesized by the pineal gland during the night, contributes to synchronize body rhythms with the environmental light/dark cycle...
March 7, 2018: British Journal of Pharmacology
S Wassink-Vossen, R M Collard, B W Penninx, S A Hiles, R C Oude Voshaar, P Naarding
BACKGROUND: The level of physical activity (PA) and the prevalence of depression both change across the lifespan. We examined whether the association between PA and depression is moderated by age. As sense of mastery and functional limitations have been previously associated with low PA and depression in older adults, we also examined whether these are determinants of the differential effect of age on PA and depression. METHODS: 1079 patients with major depressive disorder (aged 18-88 years) were followed-up after two-years; depression diagnosis and severity as well as PA were re-assessed...
March 3, 2018: European Psychiatry: the Journal of the Association of European Psychiatrists
Andrea N Goldstein-Piekarski, Brooke R Staveland, Tali M Ball, Jerome Yesavage, Mayuresh S Korgaonkar, Leanne M Williams
Default mode network (DMN) dysfunction (particularly within the anterior cingulate cortex (ACC) and medial prefrontal cortex (mPFC)) has been implicated in major depressive disorder (MDD); however, its contribution to treatment outcome has not been clearly established. Here we tested the role of DMN functional connectivity as a general and differential biomarker for predicting treatment outcomes in a large, unmedicated adult sample with MDD. Seventy-five MDD outpatients completed fMRI scans before and 8 weeks after randomization to escitalopram, sertraline, or venlafaxine-XR...
March 6, 2018: Translational Psychiatry
Marlijn Vermeiden, Astrid M Kamperman, Witte J G Hoogendijk, Walter W van den Broek, Tom K Birkenhäger
BACKGROUND: In patients suffering from major depressive disorder, non-response to initial antidepressant monotherapy is relatively common. The use of treatment algorithms may optimize and enhance treatment outcome. METHODS: A single-center 3-phase treatment algorithm was evaluated for inpatients with major depressive disorder, i.e. phase I (n = 85): 7 weeks optimal antidepressant monotherapy (imipramine or venlafaxine); phase II (n = 39): 4 weeks subsequent plasma level-targeted dose lithium addition in case of insufficient improvement of antidepressant monotherapy; and phase III (n = 8): subsequent electroconvulsive therapy in case of insufficient improvement of antidepressant‑lithium treatment...
March 2, 2018: Progress in Neuro-psychopharmacology & Biological Psychiatry
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"